Role of Peroxisome Proliferator-Activated Receptor alpha in Diabetic Nephropathy
Diabetes & Metabolism Journal
;
: 327-336, 2011.
Artigo
em Inglês
| WPRIM
| ID: wpr-210389
ABSTRACT
With a developing worldwide epidemic of diabetes mellitus, the renal complications associated with diabetes have become a serious health concern. Primary therapy for treating diabetic nephropathy is a multifactorial process. Peroxisome proliferator-activated receptor alpha (PPARalpha) agonists have been used primarily in clinical practice for the treatment of dyslipidemia and insulin resistance. Given that PPARalpha expression and regulation of metabolic pathways are involved in oxidative stress, inflammation, blood pressure regulation, and the renin-angiotensin aldosterone system, PPARalpha likely influences the development and pathogenesis of diabetic nephropathy via indirect effects on glucose and lipid homeostasis and also by direct action on the kidneys. These findings suggest that PPARalpha may become an important therapeutic target for treating diabetic renal complications.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Pressão Sanguínea
/
Resistência à Insulina
/
Estresse Oxidativo
/
Peroxissomos
/
PPAR alfa
/
Diabetes Mellitus
/
Nefropatias Diabéticas
/
Aldosterona
/
Dislipidemias
/
Redes e Vias Metabólicas
Idioma:
Inglês
Revista:
Diabetes & Metabolism Journal
Ano de publicação:
2011
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS